HOME >> MEDICINE >> NEWS
Three-year SAPPHIRE and US carotid feasibility trials demonstrate durability of carotid stenting

Washington, D.C., October 18, 2005 Preliminary three-year data from the SAPPHIRE and final three-year data from the U.S. Carotid Feasibility Study (USFS) presented at the 2005 Transcatheter Cardiovascular Therapeutics meeting, demonstrate the long-term durability of carotid artery stenting (CAS) for the prevention of stroke versus carotid endarterectomy (CEA) in high risk surgical patients.

Three hundred thirty-four patients in the SAPPHIRE trial were randomized to either CAS or CEA. Patients who received CAS with the PRECISE Nitinol Self-Expanding Stent and ANGIOGUARDTM XP Emboli Capture Guidewire System maintained a low incidence of stroke after the first 30 days for the duration of the three-year follow-up in the USFS and SAPPHIRE. In the SAPPHIRE trial, at 36 months the incidence of stroke was virtually identical for both CAS and CEA (7.1% for CAS and 6.7% for CEA, P = 0.945). The 3-year incidence of stroke across the randomized and non-randomized CAS treatment groups in SAPPHIRE and the USFS had only an average increase of 4.0% over the 30-day stroke rate. Cordis Corporation, a Johnson & Johnson company, sponsored the SAPPHIRE and USFS clinical trials.

Jay S. Yadav, M.D., the Cleveland Clinic Foundation, and a principal investigator for the SAPPHIRE trial said, "The SAPPHIRE trial demonstrated CAS was non-inferior to CEA. This is important new data which suggests the long-term durability of CAS in this patient population."

An analysis of target lesion revascularization (TLR) with follow up to three years in the randomized arms of SAPPHIRE showed reintervention rates of 3.0% for CAS and 7.1% for CEA, P = 0.084. Three-year TLR rates for CAS were similar in the USFS.

Additional Carotid Stenting Data
Data from the SAPPHIRE, USFS, and CASCADE clinical trials also were presented in two poster sessions highlighting CAS involving ANGIOGUARD. The data suggests emboli protection is effective in preventi
'"/>

Contact: Amy Meshulam
amy.meshulam@edelman.com
323-202-1065
Edelman Public Relations
18-Oct-2005


Page: 1 2

Related medicine news :

1. Capture study shows safety of carotid stenting in real-world setting
2. Training on virtual patient improves carotid angiography skills
3. Landmark trial shows carotid stenting beneficial for patients with disease but no symptoms
4. Stent-graft procedure improves outcomes of carotid aneurysm repair
5. Pitt reports re-opening of carotid arteries in stroke has high success rate with stenting
6. Statins reduce the risk of stroke and death after carotid artery surgery
7. Increased risk associated with combining carotid artery, coronary artery surgeries
8. Fifth VentrAssist implant in US feasibility trial
9. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
10. Helicopter flight trials for EGNOS
11. Bias in statin trials, failure to control malaria, and more

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 10, 2020 , ... 3Lions Publishing, Inc. (3LP), ... Partner Vetting (BPV) Portal . Expresso® 3.0 contains a Portal where potential and ... mailing, tracking, and performing other administrative tasks that amount to thousands of ...
(Date:7/4/2020)... ... July 03, 2020 , ... ... featured in Biocompare’s latest content hub— Future Lab: COVID-19 R&D . , ... advancements, trends, news, and products within specific scientific niches. Since their launch four ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... ... its annual Outstanding Safety Professional of the Year Award to Eric Simmons of ... from more than 250 nominations. Simmons, who holds a master’s degree in occupational ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera Bioscience ... psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm ... novel formulations, and as distinguished researchers within the cannabis industry. They are joined ...
(Date:6/28/2020)... ... ... PathAI, a global provider of artificial intelligence (AI)-powered technology for use in ... PD-L1 expression to assess response in patients treated with Bristol Myers Squibb’s PD-1 inhibitor, ... Research (AACR) Annual Meeting. AACR was held June 22 to June 24. , The ...
Breaking Medicine News(10 mins):
(Date:6/25/2020)... , ... June 25, 2020 , ... ... by Innovate UK to build a distributed ledger platform to store COVID-19 related ... August, Billon will provide a fully functioning prototype for publishing, sharing and verifying ...
(Date:6/25/2020)... ... June 25, 2020 , ... The FSHD Society ... , which is being conducted entirely online for the first time in the ... the discussion and dissemination of state-of-the-art research on facioscapulohumeral muscular dystrophy (FSHD). A ...
(Date:6/24/2020)... ... June 24, 2020 , ... The Safe Boating Campaign, a worldwide effort ... under the influence, or BUI, is the leading contributing factor in recreational boater deaths, ... corner, and unfortunately has become known for drinking and boating, and deadly accidents,” said ...
Breaking Medicine Technology:
Cached News: